| Revisiting the IGF-1R as a breast cancer target RC Ekyalongo, D Yee NPJ precision oncology 1 (1), 14, 2017 | 123 | 2017 |
| Direct interaction, instrumental for signaling processes, between LacCer and Lyn in the lipid rafts of neutrophil-like cells E Chiricozzi, MG Ciampa, G Brasile, F Compostella, A Prinetti, ... Journal of lipid research 56 (1), 129-141, 2015 | 58 | 2015 |
| TYRO3 as a potential therapeutic target in breast cancer RC Ekyalongo, T Mukohara, Y Funakoshi, H Tomioka, YU Kataoka, ... Anticancer research 34 (7), 3337-3345, 2014 | 39 | 2014 |
| Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification H Tomioka, T Mukohara, Y Kataoka, RC Ekyalongo, Y Funakoshi, Y Imai, ... International journal of oncology 41 (2), 551-558, 2012 | 36 | 2012 |
| Organization and functions of glycolipid-enriched microdomains in phagocytes RC Ekyalongo, H Nakayama, K Kina, N Kaga, K Iwabuchi Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2015 | 33 | 2015 |
| Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line Y Funakoshi, T Mukohara, H Tomioka, RC Ekyalongo, Y Kataoka, Y Inui, ... Investigational new drugs 31, 1158-1168, 2013 | 23 | 2013 |
| Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line RC Ekyalongo, T Mukohara, Y Kataoka, Y Funakoshi, H Tomioka, ... Investigational new drugs 31, 293-303, 2013 | 23 | 2013 |
| SELENOF is a new tumor suppressor in breast cancer A Zigrossi, LK Hong, RC Ekyalongo, C Cruz-Alvarez, E Gornick, ... Oncogene 41 (9), 1263-1268, 2022 | 18 | 2022 |
| Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells. Y Funakoshi, T Mukohara, RC Ekyalongo, H Tomioka, Y Kataoka, ... Oncology Research 21 (6), 287-293, 2013 | 2 | 2013 |
| SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells RC Ekyalongo, B Flowers, T Sharma, A Zigrossi, A Zhang, ... Cancers 15 (14), 3671, 2023 | | 2023 |
| Abstract C059: SELENOF is a novel tumor suppressor and a new target to overcome breast cancer racial disparity RC Ekyalongo, A Zigrossi, B Flowers, AM Diamond, I Kastrati Cancer Epidemiology, Biomarkers & Prevention 32 (1_Supplement), C059-C059, 2023 | | 2023 |
| Abstract P5-03-05: Model of acquired resistance to the tyrphostin NT157 in hormone receptor-positive breast cancer RC Ekyalongo, R Abdelwahab, A Holtz, A Sabet, D Yee Cancer Research 79 (4_Supplement), P5-03-05-P5-03-05, 2019 | | 2019 |
| Expression of phosphatidylglucoside in human skin disorders atopic dermatitis and psoriasis RC Ekyalongo, N Yokoyama, K Kina, H Nakayama, M Tominaga, ... Journal of Dermatological Science 84 (1), e107, 2016 | | 2016 |
| Ptdglc-Enriched Lipid Rafts Are a Novel Platform for Apoptosis Signaling in Human Neutrophilic Lineage Cells RC Ekyalongo, N Yokoyama, H Nakayama, H Ogawa, Y Tabe, ... Blood 126 (23), 4968, 2015 | | 2015 |
| Abstract C95: Reversibility of acquired resistance and “addiction” to MET inhibitors. Y Funakoshi, T Mukohara, H Tomioka, RC Ekyalongo, Y Kataoka, ... Molecular Cancer Therapeutics 12 (11_Supplement), C95-C95, 2013 | | 2013 |
| Abstract C186: Tyro3 is a potential target for the treatment of breast cancer. RC Ekyalongo, T Mukohara, Y Funakoshi, H Tomioka, Y Kataoka, ... Molecular Cancer Therapeutics 12 (11_Supplement), C186-C186, 2013 | | 2013 |
| Excessive MET Signaling Causes Acquired Resistance to and Addiction to MET Inhibitors in MKN45 Gastric Cancer Cell Line Y Funakoshi, T Mukohara, H Tomioka, RC Ekyalongo, Y Kataoka, Y Inui, ... EUROPEAN JOURNAL OF CANCER 48, 93-94, 2012 | | 2012 |
| P5-06-04: Mechanisms of Acquired Resistance to Insulin-Like Growth Factor 1 Receptor Inhibitor in MCF-7 Breast Cancer Cell Line. RC Ekyalongo, T Mukohara, Y Kataoka, N Kiyota, Y Fujiwara, H Minami Cancer Research 71 (24_Supplement), P5-06-04-P5-06-04, 2011 | | 2011 |
| Tak1 Signal Y Funakoshi, T Mukohara, RC Ekyalongo, H Tomioka, Y Kataoka, ... | | |
